Source link : https://www.newshealth.biz/health-news/treatment-effective-before-car-t/
SAN DIEGO — Single-agent epcoritamab demonstrated deep and durable responses in CAR T–naïve patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) in a subgroup analysis of the pivotal phase 2 Epcore NHL-1 trial. These findings show that epcoritamab — a bispecific antibody therapy available off the shelf and shown in the overall R/R […]
Author : News Health
Publish date : 2024-12-09 06:12:58
Copyright for syndicated content belongs to the linked Source.
Categories